The experimental drug daraxonrasib nearly doubled overall survival rates for patients with advanced pancreatic cancer in a recent clinical trial [1].
This development represents a significant shift in treating one of the deadliest forms of cancer, which has historically seen poor patient outcomes. By targeting specific proteins that were previously considered undruggable, the therapy offers a new path for patients who have exhausted standard options.
Developed by Revolution Medicines, daraxonrasib focuses on RAS oncoproteins [5]. These proteins are critical drivers of tumor growth in pancreatic cancer, but their structure made them difficult for previous generations of medicine to bind to and inhibit [5].
Clinical trials were conducted across the U.S., including sites at the Huntsman Cancer Institute in Utah [3]. The results, reported this week, show a marked improvement in survival time for patients receiving the drug compared to those receiving standard chemotherapy [1].
While some reports state the drug doubled survival time [2], other data indicates the increase was nearly double [1]. This range of success is considered unprecedented for advanced pancreatic cancer treatments [2].
Researchers said the drug's ability to target the RAS pathway allows for a more precise attack on cancer cells. This targeted approach aims to reduce the systemic toxicity often associated with traditional chemotherapy, while increasing the efficacy of the treatment [5].
“The experimental drug daraxonrasib nearly doubled overall survival rates for patients with advanced pancreatic cancer.”
The success of daraxonrasib suggests that the 'undruggable' nature of RAS oncoproteins is being overcome by new molecular engineering. If these results hold in larger trials, it could shift the standard of care for advanced pancreatic cancer from general chemotherapy to targeted precision medicine, potentially extending life expectancy for a patient population with very few effective options.
